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Abstract
Background: Epstein Barr Virus (EBV) plays a significant role as a cofactor in the process of tumorigenesis and has
consistently been associated with a variety of malignancies. EBV encoded RNAs (EBER1 and EBER2) are the most
abundant viral transcripts in latently EBV-infected cells and their role in viral infection is still unclear. Formalin Fixed
Paraffin Embedded (FFPE) tissues of surgically removed carcinoma biopsies are widely available form but have
never been exploited for expressional studies previously in Pakistan. Immunohistochemistry (IHC) and in situ
hybridization (ISH) in FFPE biopsy tissues remains the gold standard for proving EBV relationship in a
histopathological lesion but their reagents associated limitations confines their reliability in some applications.
Recently introduced targeted drug delivery systems induce viral lytic gene expression and therefore require more
sensitive method to quantify viral as well as cellular gene expression.
Methods: Eight (8) lymphoma samples were screened to detect the EBV genome. Qualitative and quantitative
expression of EBV Encoded RNAs (EBER1, EBER2) and anti-inflammatory cytokine (interleukin-10) in FFPE EBV
positive lymphoma tissue samples were then analysed by using Reverse transcriptase Polymerase Chain Reaction
(RT-PCR) and Real Time Polymerase Chain Reaction (qRT-PCR), respectively.
Results: In this study we have successfully quantified elevated expressional levels of both cellular and viral
transcripts, namely EBER1, EBER2 and anti-inflammatory cytokine (IL-10) in the FFPE Burkitt’s lymphoma (BL)
specimens of Pakistani origin.
Conclusions: These results indicate that FFPE samples may retain viral as well as cellular RNA expression
information at detectable level. To our knowledge, this is first study which represents elevated expressional levels
of EBER1, EBER2 and IL-10 in FFPE tissue samples of Burkitt’s lymphoma in Pakistan. These observations will
potentially improve current lacunas in clinical as well as diagnostic practices in Pakistan and can be further
exploited to develop new strategies for studying cellular and/or viral gene expression.
Background
Epstein-Barr virus (EBV) [1] is a ubiquitous human
g-herpes virus infecting more than 90% of the population
worldwide [2] and plays a significant role as a cofactor in
the process of tumorogenesis. It has consistently been
associated with a variety of malignancies including
endemic Burkitt’s lymphoma (BL) [1,2], nasopharyngeal
carcinoma [3,4], T-cell lymphoma, Pyothorax-associated
or methotrexate-associated B-cell lymphoma, Primary
effusion lymphoma, gastric carcinoma [5], EBV associated
hemophagocytic syndrome and approximately 50% of
Hodgkin’s diseases. Moreover it has been associated with
different types of lymphoproliferative diseases especially in
immunocompromised patients [6]. In immunocompro-
mised patients with impaired cell mediated immunity,
acute EBV infection is associated with the development of
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50-80%. In addition to that, recipients of solid organ trans-
plants, the incidence of post transplant lymphoprolifera-
tive disease (PTLD) ranges from 1% to 15% [7]. Prevalence
of EBV in Pakistani Burkitt’s lymphoma patients is 80%
which is significantly higher than in BL in North America
[8].
EBV replicates in the epithelial cells of the mouth, ton-
gue, salivary glands, and oral cavity and then it spread into
the B-cells which are the main host cell type for its latent
infection [9]. Upon entry into B cell, the EBV proteins are
expressed in a cascade manner. Every EBV-transformed
cell carries multiple extrachromosomal copies of the viral
episome and constitutively expresses a limited set of viral
gene products referred to as latent proteins, which com-
prise of: Six (6) EBV nuclear antigens (EBNAs 1, 2, 3A, 3B,
3C and -LP) [9-11], three latent membrane proteins
(LMPs 1, 2A and 2B) and transcripts from the BamHIA
region of the viral genome namely BART transcripts
[11,12]. In addition to the latent proteins, EBV-trans-
formed cell also show abundant expression of the small,
non-polyadenylated non-coding RNAs, EBER1 and
EBER2. This pattern of latent EBV gene expression, which
appears to be activated only in Burkitt’sl y m p h o m a ,i s
referred to as ‘latency I’ [9-13]. Interleukin-10 (IL-10) an
anti-inflammatory cytokine (also known as human Cyto-
kine Synthesis Inhibitory Factor (CSIF)), is known to be an
important regulator in cell transformation [14]. EBV
+
(positive) Burkitt’s lymphoma (BL) cells express high level
of IL-10 as compared to the EBV
- (negative) BL cell lines
[15]. On the other hand, the expressional levels of IL-10
are extremely low and/or negligible in normal tumour cell
lines [15,16]. Approximately 10 fold increased expression
of the IL-10 in Burkitt’s lymphoma cell lines is reported
[16]. These elevated levels of EBER and IL-10 have also
been known to increase cell’s tumorigenicity [17,18]. This
expression profile could be used as power full tool in the
expressional profiling studies as well as relative quantifica-
tion of EBERs in the tissue samples.
For tissue preservation, formalin fixation followed by
paraffin wax embedding is mostly used to maintain the
morphological features of the original tissue [19]. The
Formalin Fixed and Paraffin Embedded (FFPE) tissues
are used in various immunohistochemistry (IHC) techni-
ques for localizing Epstein-Barr viral nucleic acid and/or
protein to the tumour cells. Previously EBER in-situ
hybridization (ISH) was considered as the most excellent
test for detection and localization of latent EBV in tissue
samples [20,21]. Other techniques including automated
EBER ISH and automated LMP-1 IHC with increased
s e n s i t i v i t ya n ds p e c i f i c i t yh a v er e c e n t l yb e c a m eu s e f u l
diagnosis tool for EBV related diseases [22-24].
ISH reagents associated limitations like limited target
site accessibility and capacity to penetrate into whole
mount tissue specimens confines its reliability [25].
Although, both techniques (fluorescent in-situ hybridiza-
tion (FISH) and reverse transcriptase polymerase chain
reaction (RT-PCR)) have inevitable advantages in the
field of diagnostics but comparative evidence of more
target specificity and sensitivity of RT-PCR for the
detection of minimal residual disease in long-term mon-
itoring of patients has increased its importance in some
applications [26]. In addition to that quantitative real
time PCR which has ability to detect as low as two fold
changes in the gene expression, is rapidly replacing
immunological assays [27,28]. Numerous therapeutic
agents aiming EBV associated tumour regression are
beginning to emerge [29,30]. These targeted drug deliv-
ery systems induce viral lytic gene expression [30,31]
and therefore, require more sensitive quantitative analy-
sis of viral as well as cellular gene expression to monitor
the effect of these therapeutic treatments.
This study was aimed to develop a precise Real time
PCR based laboratory methodology to detect and quan-
tify EBV encoded RNAs in FFPE Burkit’sl y m p h o m a
samples of Pakistani origin. Furthermore, anti-inflamma-
tory cytokine (IL-10) expression in EBV
+ (positive) sam-
ples were characterized to indicate its relevance with
viral persistence in tumour cells. These studies will
introduce novel potential biomarkers as well as new
insight in the current diagnostic trends of Pakistan.
Methods
Sample Collection and Cell Culture
In total eight (8) lymphoma samples were included in
this study. The sampling was conducted at Pakistan Insti-
tute of Medical Sciences (PIMS), for routine histopatho-
logical examination. Formalin Fixation and Paraffin
Embedding (FFPE) procedures were then carefully per-
formed [32-35] on lymphoma samples individually, under
sterile conditions. After histopathological examination
three (3) samples were classified as Burkitt’sl y m p h o m a
(BL) and five (5) as non-Hodgkin lymphomas (NHLs).
EBV transformed B95-8 cell line (Kindly provided by
Dr. Sharof Tugizov Department of Medicine, University
of California, San Francisco, California USA) were main-
tained in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), 1% L-glutamine, and 1% penicillin-
streptomycin (all from Gibco, Basel, Switzerland).
Nucleic Acid Extraction and Purifications
Approximately 4 × 20 μm sections of selected samples
were taken for nucleic acid extraction and purification.
Genomic DNA was purified from Formalin-fixed Paraf-
fin embedded tissue sections by using QIAamp DNA
FFPE Tissue Kit (Qiagen).
Total RNA of the positive samples was extracted by
using PureLink™ FFPE Total RNA Isolation Kit
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turer instructions. All samples were treated with DNase
I Amplification Grade (Invitrogen Carlsbed, CA U.S.A)
to eliminate DNA contaminations.
Amplification and Detection
Before EBV specific amplifications, all DNA samples were
tested with primers to amplify a fragment of the human b
globin Genes in order to ensure DNA integrity. Initially,
nested PCR based screening for EBV presence of all lym-
phoma samples were carried out by targeting genomic
DNA of EBNA1 as recommended by Bagan JV et al, 2008
[36].
Qualitative PCR of EBV positive samples were per-
formed in total volume of 20 ul containing final concen-
trations of 100 ng genomic DNA, Taq Buffer with KCl;
2.5 units of Taq DNA polymerase, 2 mM dNTPs, 1.5
mM MgCl2 final concentration (Fermentas). In the first
round of amplification, primers for EBER1 and EBER2
(Table 1) aimed at amplifying a fragment of 166 bp and
172 bp, respectively.
Quantitative Real time PCR (qRT-PCR)
Quantitative Real time PCR (qRT-PCR) of 10 ul of Total
RNA template (50 ng) of EBV
+ (positive) and EBV
- (nega-
tive) samples were used to amplify EBER 1/EBER 2 and
IL-10 aimed primers (Table 1). Thermocycling was per-
formed at 95°C for 3 minutes, followed by 40 cycles at 94°
C for 30 s, 54°C for 30 s, and 72°C for 40 s to measure the
fluorescence signal. Quantitative analyses of the data were
carried out using 7300 system SDS software v1.4 (Applied
Biosystems, USA). Reaction concentrations and conditions
were adjusted according to the manual instructions of
SuperScript
®III Platinum
® SYBR
® Green One-Step qRT-
PCR Kit (Invitrogen Carlsbed, CA, U.S.A). Equal quantity
of RNA from B95-8 cell line (Positive control) and EBV
-
tissue sample (Negative control) were used. All experi-
ments were done in triplicate.
Purification and Sequencing
The amplified product was purified by using PureLink™
Gel Extraction Kit (Invitrogen Carlsbed, CA U.S.A)
according to the manufacturer’s instructions. The
purified product was sequenced by using Genetic Analy-
sis System Beckman Coulter (CEQ-8000 USA). These
sequences were published in Genbank, EMBL and DDBJ
[Accession Number: GU205106 &GU205107].
Date Analysis
In a real time PCR assay Ct (cycle threshold) is defined as
the number of cycles required by fluorescent signals to
cross the threshold. Ct levels are inversely proportional
to the quantity of target nucleic acid in the sample
[37,38].
In these experiments, the linear rates of expressions of
EBER1, EBER2 and IL-10 were calculated by dividing
the threshold (0.10) with respective mean CT values of
EBV
+ patients.
Results and Discussions
Epstein Barr Virus (EBV) play significantly as a cofactor
in the process of viral induced oncogenesis and asso-
ciated with a larger range of malignancies [2-5]. Here, we
have screened eight (8) FFPE lymphoma samples of for
the presence of EBV nuclear antigen (EBNA1) (Figure 1).
In addition to that, EBV encoded RNAs (EBER1 and
EBER2) are the most abundant viral transcripts in
latently EBV-infected cells [12,13] and their role in viral
infection is still unclear. In this study, we have developed
a qualitative reverse transcriptase (RT-PCR) based assay
system (Figure 2) to detect genomic fragments of EBER1
and 2 from Formalin Fixed Paraffin Embedded (FFPE)
tissue sample. The FFPE sections are most broadly avail-
able form of lymphoma tissues in Pakistan.
Viral gene expression based studies provide a better
chance to understand virally induced lymphomas at
molecular level which leads to the discoveries of potential
biomarkers and therapeutic agents [39-41]. Several drugs
involved in tumour degeneration require knowledge of
change in gene expression in diseased tissues [30,31].
Furthermore, FFPE samples have not yet been analytically
investigated with respect to viral gene expression in Paki-
stan. We have for the first time purified, amplified (Fig-
ure 3) and sequenced [Genbank, EMBL, DDBJ Accession
Number: GU205106 &GU205107] viral RNAs from the
FFPE Burkit’s lymphoma tissue samples. These results
Table 1 Specification of Primers used in RT-PCR and qRT-PCR Experiments
S. No. Target Gene Primer Name Primer Sequence 5’———————————————3’
1) EBV encoded RNA 1 (EBER1) EB1 (Forward)
EB1 (Reverse)
5’- AGGACCTACGCTGCCCTAGA -3’
5’- AAAACATGCGGACCACCAGCTGG -3’
2) EBV encoded RNA 2 (EBER2) EB2 (Forward)
EB2 (Reverse)
5’- AGGACAGCCGTTGCCCTAGTG -3’
5’- TAGCGGACAAGCCGAATACCCT -3’
3) Interleukin 10 (IL10), mRNA IL-10 (Forward)
IL-10 (Reverse)
5’- ATGCACAGCTCAGCACTGCTCTG -3’
5’- GGAAGAAATCGATGACAGCGCCG -3’
4) Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), mRNA GAP (Forward)
GAP (Reverse)
5’- CAAGGTCATCCATGACAACTTTG -3’
5’- GTCCACCACCCTGTTGCTGTAG -3’
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more prominently in viral RNA profiling studies. In addi-
tion to that, we have also developed a real time PCR
based assay in which a novel comparison of viral and
cellular RNA is illustrated (Figure 4). This was done on
the bases of an observation that expression of IL-10
mRNA was negligibly low in normal EBV negative lym-
phoma tissues [14-17]. We have successfully quantified
50bp     1                2         3        4        5        6        7        8 
EBNA1
FFPE Lymphoma Samples
Figure 1 Results of agarose Gel Electrophoresis of EBNA 1 genomic DNA (left-to-right): Lane 1 shows the 50 bp DNA ladder, Lane 2-3
represents the EBNA1 positive Burkitt’s lymphoma samples (100 bp Nested PCR amplified product), Lane 4 represents EBNA1 Negative Burkitt’s
lymphoma (BL) samples, Lane 5,6,7,8 represents EBNA1 Negative non-Hodgkin lymphomas (NHLs) samples.
50bp               1                   2                 3                 50bp
Figure 2 Qualitative PCR assay system: Results of Agarose Gel Electrophoresis of EBER1 and EBER2 genomic DNA fragment in EBV positive
Burkitt’s lymphoma (BL) samples. Lane 1 (left-to-right) 50 bp ladder, Lane 2 166 bp EBER1, Lane 3 172 bp EBER2, Lane 4 EBER 2 172 bp (B95-8),
positive control, Lane 5 50 bp ladder.
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GAPDH
Figure 3 Electropherogram showing semi-quantitative RT-PCR based analysis of EBER1 and EBER2 (left-to-right): Lane 1 (100 bp ladder),
Lane 2 transcript of EBER1 (166 bp), Lane 3 transcript of EBER2 (172 bp), Lane 4 50 bp ladder. All samples were normalized with GAPDH as
reference genes.
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Figure 4 Real-time PCR based Quantitative analysis of EBER1, EBER2 and IL-10 transcripts: Real-time PCR was performed to determine the
expression status of IL-10, EBER1 and EBER2. GAPDH was used as a reference gene to normalize expression of all samples. Expression levels of
EBER1 (A), EBER2 (B) and IL-10(C) in EBV infected Burkitt’s lymphoma samples were quantified and compared to uninfected samples as negative
controls. Data are shown after log transformation.
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encoded viral RNAs in comparison with normal EBV
-
subjects (Figure 5). These observations can be further
used to develop precise laboratory techniques with
increased reliability.
Conclusions
Expression of both viral RNA and cellular RNA are sig-
nificantly high, in comparison with normal EBV
- (nega-
tive) lymphoma tissues. These results suggested that
RNA isolated from FFPE samples preserve the majority
of the characteristic expression. In addition to that ele-
vated expression of anti-inflammatory cytokine (IL-10)
was observed in the EBV
+ (positive) samples in compari-
son with EBV
- samples (undetectable or negligibly low
levels of expression) which indicate its relevance with
viral persistence in EBV transformed tumour cells.
These studies will open novel avenues to study cellular
and/or viral gene expression and will introduce new bio-
markers and strategies to improve clinical as well as
diagnostic practices in Pakistan.
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